Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2024-211410

Published: 2024

Journal Articles

Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades

Luis Gerardo Rodríguez-Lobato, Anna De Daniel, Arturo Pereira, Carlos Fernández de Larrea, Natalia Tovar, M Teresa Cibeira López, David F. Moreno, José Miguel Mateos Pérez, Joan Bladé, Laura Rosinol Dachs

Blood (2024) 144 (Supplement 1): 3321.

https://doi.org/10.1182/blood-2024-202549

Published: 2024

Journal Articles

Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Valentin Ortiz-Maldonado, Nuria Martínez-Cibrián, Leticia Alserawan, Sergi Betriu, Ana Triguero, Sandra Blum, Margaux Faes, Marte C. Liefaard, Margot J. Pont, Maike Spoon, Kirsten Van Hoorde, Anna D. D. van Muyden, Julio Delgado, Natalia Tovar

Blood (2024) 144 (Supplement 1): 3452.

https://doi.org/10.1182/blood-2024-207546

Published: 2024

Journal Articles

Outcomes of Patients with Relapsed Multiple Myeloma Treated with Pomalidomide, Cyclophosphamide, and Dexamethasone Based on Prior Resistance to Anti-CD38 Monoclonal Antibodies

Marta Hidalgo-Soto, Lucía Martín-Rodríguez, Eugenia Abella Montreal, Inmaculada Fernández-Camacho, Mercedes Gironella Mesa, Yolanda González-Montes, M Teresa Cibeira López, Laura Rosinol Dachs, José Miguel Mateos Pérez, Natalia Tovar, Carlos Fernández de Larrea, Luis Gerardo Rodríguez-Lobato

Blood (2024) 144 (Supplement 1): 6955.

https://doi.org/10.1182/blood-2024-200627

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

Luis Gerardo Rodríguez-Lobato, Oriol Cardus, Joan Mañé Pujol, Anthony Battram, David F. Moreno, Lorena Perez-Amill, Beatriz Martín-Antonio, Aina Oliver-Caldés, Anna De Daniel, Natalia Tovar, M Teresa Cibeira López, Laura Rosinol Dachs, Manel Juan, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea

Blood (2024) 144 (Supplement 1): 359.

https://doi.org/10.1182/blood-2024-200123

Published: 2024

Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial

Natalia Tovar, Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Sergi Betriu, Daniel Esteban, Ana Triguero, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden

Blood (2023) 142 (Supplement 1): 2112.

https://doi.org/10.1182/blood-2023-189321

Published: 2023

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Blood (2023) 142 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2023-173311

Published: 2023

Journal Articles

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10281–10282.

https://doi.org/10.1182/blood-2022-166764

Published: 2022

Journal Articles

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

Luis Gerardo Rodríguez-Lobato, Anna de Daniel i Bisbe, Natalia Tovar, Raquel Jiménez-Segura, M. Teresa Cibeira, David F. Moreno, Aina Oliver-Caldes, Alexandra Martínez-Roca, Ester Lozano, Joan Bladé Creixenti, Laura Rosinol Dachs, Carlos Fernandez de Larrea

Blood (2022) 140 (Supplement 1): 4341–4342.

https://doi.org/10.1182/blood-2022-165371

Published: 2022

Journal Articles

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Blood (2022) 140 (Supplement 1): 10347–10349.

https://doi.org/10.1182/blood-2022-166525

Published: 2022

Journal Articles

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

David F. Moreno, Sara Paz, Mari-Pau Mena, Monica Lopez-Guerra, Aina Oliver-Caldes, Anthony M Battram, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, M. Teresa Cibeira, Raquel Jiménez-Segura, Joan Bladé Creixenti, Laura Rosinol, Dolors Colomer, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 462.

https://doi.org/10.1182/blood-2021-147168

Published: 2021

Journal Articles

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2837.

https://doi.org/10.1182/blood-2021-147188

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Andrew M. Brunner, Elie Traer, Norbert Vey, Sebastian Scholl, Natalia Tovar, Kimmo Porkka, Rupa Narayan, Guillermo Garcia-Manero, Steve Knapper, Martin Wermke, Jeroen J. Janssen, Jordi Esteve, Sun Loo, Mika Kontro, Zachariah Defilipp, Andrew H. Wei, Uma Borate

Blood (2021) 138 (Supplement 1): 3677.

https://doi.org/10.1182/blood-2021-151455

Published: 2021

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Blood (2021) 138 (Supplement 1): 244.

https://doi.org/10.1182/blood-2021-146039

Published: 2021

Journal Articles

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Ignacio Isola, MD, David Moreno, MD, Esther Moga, MD PhD, Mari-Pau Mena, PhD, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, MD PhD, M. Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Carlos Fernandez de Larrea, MD PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-139737

Published: 2020

Journal Articles

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137307

Published: 2020

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136855

Published: 2020

Journal Articles

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 570.

https://doi.org/10.1182/blood-2019-128178

Published: 2019

NARROW

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades

Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Outcomes of Patients with Relapsed Multiple Myeloma Treated with Pomalidomide, Cyclophosphamide, and Dexamethasone Based on Prior Resistance to Anti-CD38 Monoclonal Antibodies

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only